Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Broparestrol** is a synthetic, nonsteroidal **selective estrogen receptor modulator (SERM)** of the **triphenylethylene** group, chemically described as **α-bromo-α,β-diphenyl-β-p-ethylphenylethylene (BDPE)**. It exhibits slightly **estrogenic** and potently **antiestrogenic** properties, inhibiting mammary gland development and suppressing prolactin levels in animals. Used in Europe as a **dermatological agent** and for **breast cancer** treatment, it is structurally related to clomifene and diethylstilbestrol, and exists as a mixture of **E-** and **Z-isomers** (LN-1643 and LN-2299), both active but never individually marketed.[1][4][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on broparestrol.